Rapid Emergence of SARS-CoV-2 in the Greater New York Metropolitan Area: Geolocation, Demographics, Positivity Rates, and Hospitalization for 46 793 Persons Tested by Northwell Health.
coronavirus disease 2019 (COVID-19)
hospitalization
race
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
socioeconomic
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
12
05
2020
accepted:
07
07
2020
pubmed:
9
7
2020
medline:
28
1
2021
entrez:
9
7
2020
Statut:
ppublish
Résumé
In March 2020, the greater New York metropolitan area became an epicenter for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The initial evolution of case incidence has not been well characterized. Northwell Health Laboratories tested 46 793 persons for SARS-CoV-2 from 4 March through 10 April. The primary outcome measure was a positive reverse transcription-polymerase chain reaction test for SARS-CoV-2. The secondary outcomes included patient age, sex, and race, if stated; dates the specimen was obtained and the test result; clinical practice site sources; geolocation of patient residence; and hospitalization. From 8 March through 10 April, a total of 26 735 of 46 793 persons (57.1%) tested positive for SARS-CoV-2. Males of each race were disproportionally more affected than females above age 25, with a progressive male predominance as age increased. Of the positive persons, 7292 were hospitalized directly upon presentation; an additional 882 persons tested positive in an ambulatory setting before subsequent hospitalization, a median of 4.8 days later. Total hospitalization rate was thus 8174 persons (30.6% of positive persons). There was a broad range (>10-fold) in the cumulative number of positive cases across individual zip codes following documented first caseincidence. Test positivity was greater for persons living in zip codes with lower annual household income. Our data reveal that SARS-CoV-2 incidence emerged rapidly and almost simultaneously across a broad demographic population in the region. These findings support the premise that SARS-CoV-2 infection was widely distributed prior to virus testing availability.
Sections du résumé
BACKGROUND
In March 2020, the greater New York metropolitan area became an epicenter for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The initial evolution of case incidence has not been well characterized.
METHODS
Northwell Health Laboratories tested 46 793 persons for SARS-CoV-2 from 4 March through 10 April. The primary outcome measure was a positive reverse transcription-polymerase chain reaction test for SARS-CoV-2. The secondary outcomes included patient age, sex, and race, if stated; dates the specimen was obtained and the test result; clinical practice site sources; geolocation of patient residence; and hospitalization.
RESULTS
From 8 March through 10 April, a total of 26 735 of 46 793 persons (57.1%) tested positive for SARS-CoV-2. Males of each race were disproportionally more affected than females above age 25, with a progressive male predominance as age increased. Of the positive persons, 7292 were hospitalized directly upon presentation; an additional 882 persons tested positive in an ambulatory setting before subsequent hospitalization, a median of 4.8 days later. Total hospitalization rate was thus 8174 persons (30.6% of positive persons). There was a broad range (>10-fold) in the cumulative number of positive cases across individual zip codes following documented first caseincidence. Test positivity was greater for persons living in zip codes with lower annual household income.
CONCLUSIONS
Our data reveal that SARS-CoV-2 incidence emerged rapidly and almost simultaneously across a broad demographic population in the region. These findings support the premise that SARS-CoV-2 infection was widely distributed prior to virus testing availability.
Identifiants
pubmed: 32640030
pii: 5868956
doi: 10.1093/cid/ciaa922
pmc: PMC7454448
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3204-3213Subventions
Organisme : NLM NIH HHS
ID : R01 LM012836
Pays : United States
Organisme : NIA NIH HHS
ID : R24 AG064191
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Science. 2020 Jul 17;369(6501):297-301
pubmed: 32471856
Int J Health Geogr. 2006 Dec 13;5:58
pubmed: 17166283
Genome Res. 2020 Dec;30(12):1781-1788
pubmed: 33093069
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Am J Public Health. 2015 Sep;105(9):e27-34
pubmed: 26180961
J Racial Ethn Health Disparities. 2018 Aug;5(4):712-720
pubmed: 28791583
Emerg Infect Dis. 2020 Jun;26(6):1341-1343
pubmed: 32191173
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
Emerg Infect Dis. 2020 May;26(5):1049-1052
pubmed: 32053479
Clin Infect Dis. 2020 Nov 5;71(8):1953-1959
pubmed: 32382743
Arch Pathol Lab Med. 2019 Dec;143(12):1517-1530
pubmed: 31100013
Int J Infect Dis. 2020 Jun;95:308-310
pubmed: 32334115